drugset / Trial / NCT04267393
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH).
Timeline
- Start
- 2021-03-17
- Primary completion
- 2023-08-16
- Completion
- 2024-02-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986263 | Small interfering RNA (siRNA) | — | — |